4 studies found for:    SGN-CD33A
Show Display Options
Rank Status Study
1 Recruiting A Safety Study of SGN-CD33A in AML Patients
Conditions: Acute Myelogenous Leukemia;   Acute Myeloid Leukemia;   Acute Promyelocytic Leukemia;   APL
Interventions: Drug: HMA;   Drug: SGN-CD33A
2 Completed A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
Condition: Acute Myeloid Leukemia
Interventions: Drug: Lintuzumab (SGN-33);   Drug: Low dose cytarabine;   Drug: Placebo
3 Completed A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Disorders;   Chronic Myelomonocytic Leukemia
Intervention: Drug: lintuzumab
4 Completed A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
Condition: Myelodysplastic Syndrome (MDS)
Interventions: Drug: lintuzumab;   Drug: lenalidomide

Indicates status has not been verified in more than two years